Anushree Sreeja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anushree Sreeja has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Adithya Kaladevi
School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam 690525, India
1 shared publication - Adithyan Rajasekhar
School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam 690525, India
1 shared publication - Aswathy Alangode
School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam 690525, India
1 shared publication - Bipin Nair
School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam 690525, Kerala, India
1 shared publication - Devika Anuja
School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam 690525, India
1 shared publication - Goutham Remesh
School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam 690525, India
1 shared publication
Latest Publications
- Open Access
- 30 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6830
Role of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities
Snakebite envenomation causes severe tissue damage, often resulting in permanent disability with long-term complications like amputations and organ dysfunction. Current antivenoms, which are antibody-based, have lower tissue penetrability and limited efficacy in minimizing the local effects, highlighting the need for adjunct therapies. Emerging evidence indicates that venom-induced pathology is not restricted to direct cytotoxicity and necrosis; rather, it also involves multiple interconnected Regulated Cell Death (RCD) pathways, but their mechanistic interplay and therapeutic implications remain poorly understood. This review examines how venom toxins induce a cellular stress response characterized by oxidative stress, membrane disruption, and calcium overload, leading to the activation of interconnected regulated cell death (RCD) pathways, including apoptosis, ferroptosis, and pyroptosis, together with autophagy and mitophagy, which primarily function as cellular stress responses that modulate these forms of regulated cell death. We further discuss the crosstalk between these RCD pathways and emerging therapeutic approaches targeting these mechanisms. Understanding these interconnected RCD pathways may facilitate the development of adjunct therapies that complement antivenom, reduce snakebite-induced morbidity, and improve clinical outcomes.
- 30 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6830
Open AccessRole of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities
Snakebite envenomation causes severe tissue damage, often resulting in permanent disability with long-term complications like amputations and organ dysfunction. Current antivenoms, which are antibody-based, have lower tissue penetrability and limited efficacy in minimizing the local effects, highlighting the need for adjunct therapies. Emerging evidence indicates that venom-induced pathology is not restricted to direct cytotoxicity and necrosis; rather, it also involves multiple interconnected Regulated Cell Death (RCD) pathways, but their mechanistic interplay and therapeutic implications remain poorly understood. This review examines how venom toxins induce a cellular stress response characterized by oxidative stress, membrane disruption, and calcium overload, leading to the activation of interconnected regulated cell death (RCD) pathways, including apoptosis, ferroptosis, and pyroptosis, together with autophagy and mitophagy, which primarily function as cellular stress responses that modulate these forms of regulated cell death. We further discuss the crosstalk between these RCD pathways and emerging therapeutic approaches targeting these mechanisms. Understanding these interconnected RCD pathways may facilitate the development of adjunct therapies that complement antivenom, reduce snakebite-induced morbidity, and improve clinical outcomes.